JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Case Report
A case report of relapsed/refractory primary central nervous system lymphoma
Abstract
Primary central nervous system lymphoma (PCNSL) is a rare aggressive non-Hodgkin's lymphoma outside the lymph nodes. Currently, high-dose chemotherapy based on methotrexate(MTX) is the standard induction treatment for newly diagnosed PCNSL but effective treatment of relapsed/refractory and elderly PCNSL is still unclear. With the advancement of clinical trials, new drugs and combination therapies such as rituximab and ibrutinib are constantly emerging, increasing the remission rate of resistant and relapsed patients . In this case report, we will try to present a case of relapsed/refractory primary central nervous system lymphoma.

Keywords : Primary central nervous system lymphoma, diffuse large B cell lymphoma, medical and radiation therapy

Download Article


1. Yi-Jian Chen BNH, Xiang Yang YPY. New advances in the treatment ofprimary central nervous system lymphoma--review. Article in Chinese.2021;29(2):633-637.
2. Ugonma N. Chukwueke LN. Central nervous systeml ymphoma.Hematol Oncol Clin North Am.2019;33(4):597-611.
3. Ferreri TC, Steffanoni FG. How we treat primary central nervoussystem lymphoma. ESMO Open. 2021;6(4):1-5.
4. Pierre Gigilio LBN. Central nervous system cancers. J Natl Compr CancNetw. 2023;(1):37-45.
5. Sophie LL, Caroline H, Carole S. Primary CNS lymphoma at firstrelapse/progression: characteristics, management, and outcome of 256patients from the French LOC network. Neuro Oncol. 2016;18(9):1297-1303. doi:10.1093/neuonc/now033
6. Grommes C, Tang SS, Wolfe J. Phase 1b trial of an ibrutinib-basedcombination therapy in recurrent/refractory CNS lymphoma. Blood.2019;133(5):436-445. doi:10.1182/blood-2018-09-875732
7. Rubenstein JL, Geng H, Fraser EJ. Phase 1 investigation oflenalidomide/rituximab plus outcomes of lenalidomide maintenance inrelapsed CNS lymphoma. Blood Adv. 2018;2(13):1595-1607. doi:10.1182/bloodadvances.2017014845
8. Frigault MJ, Dietrich J, Martinez-Lage M. Tisagenlecleucel CAR T-celltherapy in secondary CNS lymphoma. Blood. 2019;134(11):860-866.doi:10.1182/blood.2019001694.
Article available in :
Volume 2, Issue 3, 2024
Page : 76-78
https://doi.org/10.51271/JCHOR-0043
Article Information
Received : 21 May 2024
Accepted : 11 Haz 2024
Published : 01 Ağu 2024
Corresponding Author :

Zekeriya Aksöz: Department of Adult Hematology, Elazığ Medikal Hospital, Elazığ, Turkiye

[email protected]
Citation : Aksöz Z. A case report of relapsed/refractory primary central nervous system lymphoma. J Curr Hematol Oncol Res. 2024; 2(3):76-78.

Read: 213
Cited: 0
Download : 199
_Footer